Doliprane's Future: Macron's Assurance Amidst Controversial CD&R Negotiations

Monday, 14 October 2024, 12:00

Doliprane remains at the forefront as Macron and Bercy require guarantees for its future, amidst negotiations with American fund CD&R. The stakes are high for the iconic French medication.
Lefigaro
Doliprane's Future: Macron's Assurance Amidst Controversial CD&R Negotiations

Government's Response to CD&R Deal

The French government has taken a firm stance regarding the potential sale of Doliprane to the American investment fund CD&R. The Minister of Economy visited the Sanofi factory in Lisieux to reassure employees and outline essential commitments.

Key Government Demands

  • Continuous Production: Doliprane must be produced in France.
  • Retention of Headquarters: The social headquarters of Opella should remain in France.
  • Employment Preservation: Safeguarding jobs within the company is paramount.

During these discussions, Macron emphasized the importance of maintaining national sovereignty in medication production.

Investor Communication and Future Prospects

The government is engaging in talks with CD&R and Sanofi, ensuring commitments are met without deterring foreign investments. Minister Antoine Armand highlighted the importance of having serious partners to foster industrial growth.

Strategic Importance of Doliprane

  • Healthcare Security: Doliprane stands as a strategic medication for France.
  • Investment Necessity: CD&R's financial backing is seen as crucial for Opella's growth and market competitiveness.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the latest insights and trends from around the world. Stay informed and elevate your global perspective effortlessly.

Subscribe